{"links":{"html":"https://www.erudio.com/reports/dreamm-10-nct06679101","json":"https://www.erudio.com/reports/dreamm-10-nct06679101.json","markdown":"https://www.erudio.com/reports/dreamm-10-nct06679101.md","mcp":{"server":"https://mcp.erudio.com/mcp","tool":"get_report_card","arguments":{"slug":"dreamm-10-06679101"}},"request":"https://www.erudio.com/contact?report=dreamm-10-06679101"},"offer":{"cited_commentary_sources":41,"verified_hcp_statements":349,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":1950,"identity_verified_people":25,"optional":true,"price_per_verified_person_usd":15,"price_usd":375,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":1950,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_tools":["create_order","get_order","recover_key"],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"dreamm-10-nct06679101"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=dreamm-10-06679101","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/dreamm-10-nct06679101","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"deep","size_rule":"Deep: 301+ verified statements","updates_usd":{"3_months":3400,"6_months":4900,"12_months":6800},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-25T02:04:17.218010Z","notify_subscribers":false,"status":"new","summary":{"reason":"Initial accepted edition has no weekly change log.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":13,"no_commentary_found":1},"aspects":[{"claim_count":5,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":2,"title":"Primary endpoint: PFS"},{"claim_count":9,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":6,"title":"Primary endpoint: Number of Participants Achieving MRD Negative Status"},{"claim_count":11,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes","source_count":6,"title":"Secondary endpoints"},{"claim_count":13,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":8,"title":"Population and setting"},{"claim_count":14,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":7,"title":"The comparison"},{"claim_count":19,"coverage":"discussed","id":"T6","registry_field":"outcomesModule","source_count":9,"title":"Safety and tolerability"},{"claim_count":0,"coverage":"no_commentary_found","id":"T7","registry_field":"designModule","source_count":0,"title":"Design and conduct"},{"claim_count":21,"coverage":"discussed","id":"A1","source_count":14,"title":"Starting exposure, dosing intervals and induction–maintenance trade-offs"},{"claim_count":24,"coverage":"discussed","id":"A2","source_count":6,"title":"Eye-care access, monitoring research and treatment coordination"},{"claim_count":17,"coverage":"discussed","id":"A3","source_count":6,"title":"Addition versus replacement and the evolving frontline alternatives"},{"claim_count":27,"coverage":"discussed","id":"A4","source_count":6,"title":"Treatment duration, sustained MRD and the shared Rd backbone"},{"claim_count":5,"coverage":"discussed","id":"A5","source_count":3,"title":"Consequences of initial treatment for later BCMA and CD38 options"},{"claim_count":17,"coverage":"discussed","id":"A6","source_count":7,"title":"Community reach, access-dependent selection and patient support"},{"claim_count":26,"coverage":"discussed","id":"A7","source_count":10,"title":"Supporting-study comparability and changing comparator expectations"}],"counts":{"cited_sources":41,"claims_by_expression_type":{"comparison":33,"experience":39,"interpretation":44,"opinion":52,"primary_context":4,"question":35,"restatement":42,"uncertainty":29,"unspecified":71},"claims_by_kind":{"attributed_opinion":12,"interpretation":18,"limitation":1,"source_observation":318},"clinician_statements":284,"evidence_units":198,"findings":8,"people_cited":31,"people_identity_verified":25,"people_total":32,"screened_sources":166,"verified_claims":349},"depth":"rich","findings_index":[{"id":"F1","structure":{"claims":14,"claims_by_group":{"comparisons":1,"experience":1,"questions":2,"restated":1,"views":9},"has_counterview":true,"limitations":3,"links":{"context":4,"support":14},"ma_question":true,"named_voices":7,"passages":11,"sources":6,"sources_by_kind":{"commentary":4,"media":2}},"title":"A frontline role is disputed and, for some clinicians, explicitly access-dependent"},{"id":"F2","structure":{"claims":29,"claims_by_group":{"comparisons":4,"experience":2,"questions":5,"restated":4,"views":14},"has_counterview":true,"limitations":3,"links":{"context":18,"support":34},"ma_question":true,"named_voices":9,"passages":24,"sources":7,"sources_by_kind":{"commentary":1,"media":6}},"title":"Replacing daratumumab is a different question from adding belantamab"},{"id":"F3","structure":{"claims":21,"claims_by_group":{"comparisons":5,"experience":0,"questions":5,"restated":2,"views":9},"has_counterview":true,"limitations":4,"links":{"context":4,"support":25},"ma_question":true,"named_voices":13,"passages":19,"sources":14,"sources_by_kind":{"commentary":7,"media":7}},"title":"Dose spacing is viewed as an efficacy–tolerability window, not simply less treatment"},{"id":"F4","structure":{"claims":29,"claims_by_group":{"comparisons":3,"experience":0,"questions":9,"restated":14,"views":3},"has_counterview":true,"limitations":4,"links":{"context":13,"support":31},"ma_question":true,"named_voices":8,"passages":19,"sources":10,"sources_by_kind":{"commentary":1,"media":9}},"title":"Strong efficacy expectations remain extrapolations, not DREAMM-10 findings"},{"id":"F5","structure":{"claims":36,"claims_by_group":{"comparisons":4,"experience":10,"questions":8,"restated":5,"views":9},"has_counterview":true,"limitations":4,"links":{"context":15,"support":41},"ma_question":true,"named_voices":8,"passages":23,"sources":8,"sources_by_kind":{"commentary":1,"media":7}},"title":"Ocular recovery and response during holds do not eliminate patient burden"},{"id":"F6","structure":{"claims":24,"claims_by_group":{"comparisons":1,"experience":4,"questions":3,"restated":13,"views":3},"has_counterview":true,"limitations":3,"links":{"context":12,"support":26},"ma_question":true,"named_voices":7,"passages":17,"sources":6,"sources_by_kind":{"commentary":2,"media":4}},"title":"Questionnaire-led monitoring is a research prospect, not an established replacement for eye examinations"},{"id":"F7","structure":{"claims":30,"claims_by_group":{"comparisons":1,"experience":3,"questions":4,"restated":6,"views":16},"has_counterview":true,"limitations":5,"links":{"context":6,"support":38},"ma_question":true,"named_voices":7,"passages":20,"sources":6,"sources_by_kind":{"commentary":1,"media":5}},"title":"Duration, risk and frailty complicate a simple escalation narrative"},{"id":"F8","structure":{"claims":5,"claims_by_group":{"comparisons":1,"experience":1,"questions":0,"restated":0,"views":3},"has_counterview":false,"limitations":3,"links":{"context":0,"support":5},"ma_question":true,"named_voices":3,"passages":3,"sources":3,"sources_by_kind":{"media":3}},"title":"Preservation of later BCMA options is an explicitly tentative rationale"}],"medical_affairs_question":"For which transplant-ineligible patients would an access advantage justify the ocular-monitoring and functional burden compared with DRd or a CD38-containing quadruplet?","sections":{"analysis":[{"id":"section-1","level":2,"title":"A selective frontline role, not agreed adoption"},{"id":"section-2","level":2,"title":"The decision is replacement, not automatic intensification"},{"id":"section-3","level":2,"title":"Dosing is an efficacy–tolerability window"},{"id":"section-4","level":2,"title":"Optimism precedes target-trial outcomes"},{"id":"section-5","level":2,"title":"Ocular recovery and response during holds do not erase patient burden"},{"id":"section-6","level":2,"title":"Eye-care simplification remains investigational"},{"id":"section-7","level":2,"title":"Duration and frailty may matter as much as early MRD depth"},{"id":"section-8","level":2,"title":"Preserving later options is plausible to some clinicians, not established"},{"id":"section-9","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F4","shared_claims":5}],"id":"T1","label":"Primary endpoint: PFS"},{"findings":[{"id":"F4","shared_claims":7},{"id":"F5","shared_claims":1},{"id":"F7","shared_claims":1}],"id":"T2","label":"Primary endpoint: Number of Participants Achieving MRD Negative Status"},{"findings":[{"id":"F4","shared_claims":3},{"id":"F5","shared_claims":6},{"id":"F7","shared_claims":1},{"id":"F8","shared_claims":1}],"id":"T3","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":8},{"id":"F2","shared_claims":2},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":1},{"id":"F7","shared_claims":1}],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F2","shared_claims":10},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":3}],"id":"T5","label":"The comparison"},{"findings":[{"id":"F3","shared_claims":2},{"id":"F5","shared_claims":15},{"id":"F6","shared_claims":2}],"id":"T6","label":"Safety and tolerability"},{"findings":[],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-25T02:04:17.218010Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-25T16:54:06Z","record_hash":"5d61937e26e9c2896d5ba4de14c26a57b7ae712f6f926f7231c9ab71243b11c6","release_hash":"9984acebd41e416bc77ceaa5fc548e3353a46378d7866711ea0f567b4a14d4f0","report_id":"erudio-nct06679101","run_id":"94484894-bc02-4323-b885-30c48f241c53","schema_version":"5.0","slug":"dreamm-10-06679101","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"DREAMM-10 asks whether belantamab can replace daratumumab alongside lenalidomide and dexamethasone for newly diagnosed multiple myeloma in patients ineligible for transplantation. Clinicians in the sources reviewed for this edition disagree about a frontline role, with some views conditional on access. They express enthusiasm about efficacy expectations while scrutinizing dose spacing and ocular burden. Comparative benefit and the choice between replacement and combination remain unresolved.","meta_description":"166 sources screened · 349 verified statements (284 from speakers with a confirmed clinical role) from 41 sources · 8 findings. Updated Oct 25, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-d30b1070d81bdf803351"],"id":"F4","paraphrase":"A speaker in a YouTube discussion asked whether belantamab-Rd could match or improve on daratumumab-Rd in DREAMM-10.","publication_caveats":{"reason":"Publication-caveat information is not available for this source.","status":"not_set"},"source_channel":"youtube","source_date":"2026-01-02","title":"Strong efficacy expectations remain extrapolations, not DREAMM-10 findings"},{"cited_claim_ids":["claim-c7ec2b2f679736f306c0-0233d33c"],"id":"F3","paraphrase":"A participant in an X thread asked how the starting belantamab dose was selected for DREAMM-10.","publication_caveats":{"reason":"Publication-caveat information is not available for this source.","status":"not_set"},"source_channel":"x_thread","source_date":"2026-04-18","title":"Dose spacing is viewed as an efficacy–tolerability window, not simply less treatment"}]},"publication":{"approved_at":"2026-10-25T16:54:06Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":166},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","For 1 recording, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.","Some clinician views in the sources used in this report are not yet captured as evidence in this edition; the next refresh takes them up.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","Out of scope: 57 passages in the reviewed sources discuss other trials or topics outside this report's scope; they are not part of this edition.","556 statements in the sources reviewed for this edition discuss other treatment settings or topics unrelated to this trial's question and are not included.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The sources reviewed for this edition are not a representative survey of HCP opinion. Repeated statements and reposts do not establish independent agreement.","No publication reporting DREAMM-10 outcomes was identified, and a full trial protocol was not available. Supporting-study findings and prospective expectations cannot be read as target-trial results.","Some potentially relevant discussion of sequencing, community uptake, financial burden and comparative efficacy was not fully assessed. The report may therefore omit consequential qualifications or additional views.","Coverage based on trial names and related terminology may miss unnamed references or alternative transcriptions.","Some recorded passages were available only in their original transcript, leaving uncertainty about exact wording or speaker identification. Unidentified speakers remain unnamed.","Regulatory documents were not comprehensively assessed. Monitoring and access statements reflect their source, date and jurisdiction, not a verified current standard everywhere.","Small dose cohorts, differing follow-up, different regimens and inconsistent MRD or ocular-assessment denominators limit comparisons across the supporting studies.","Some speakers described different DREAMM-10 dosing intervals. The reviewed material does not resolve those differences.","Transplant-ineligible, transplant-deferred and quad-eligible populations are not interchangeable; related quadruplet discussions do not establish the same benefit–risk balance for all DREAMM-10 patients."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":1,"other":0,"podcast":5,"publication":0,"registry":0,"regulatory":0,"x_thread":25,"x_video":0,"youtube":10},"by_evidence_role":{"commentary":41},"count":41,"evidence_window":{"end":"2026-10-17","start":"2024-02-07"},"retrieval_snapshot":"2026-10-24T14:15:47.724486Z","timeline":[{"count":1,"week":"2024-W06"},{"count":1,"week":"2024-W27"},{"count":2,"week":"2024-W45"},{"count":11,"week":"2024-W49"},{"count":1,"week":"2025-W08"},{"count":1,"week":"2025-W18"},{"count":1,"week":"2025-W22"},{"count":1,"week":"2025-W23"},{"count":1,"week":"2025-W26"},{"count":2,"week":"2025-W29"},{"count":1,"week":"2025-W31"},{"count":2,"week":"2025-W42"},{"count":1,"week":"2025-W46"},{"count":1,"week":"2025-W49"},{"count":1,"week":"2026-W01"},{"count":1,"week":"2026-W15"},{"count":1,"week":"2026-W16"},{"count":2,"week":"2026-W22"},{"count":1,"week":"2026-W23"},{"count":1,"week":"2026-W25"},{"count":1,"week":"2026-W30"},{"count":1,"week":"2026-W32"},{"count":2,"week":"2026-W39"},{"count":1,"week":"2026-W40"},{"count":2,"week":"2026-W41"},{"count":1,"week":"2026-W42"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT06679101:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06679101:context","quote_policy":"short_quote_link_out"},{"id":"openfda:1b2716cf-24b4-4157-a218-58ede63917bd:20260527","quote_policy":"short_quote_link_out"},{"id":"openfda:11f10a47-1c42-40e4-89d8-bb000fef497c:20260909","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-biels5atxkvzjswr4pyndz6v-3lclkaqhkxs24","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-gfetuuiqv2f3vrr7j2fxvpfq-3mv77pgbow327","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-xwwnmzvco4pljtw3zwdxvoye-3lcbp7sh73s24","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-xwwnmzvco4pljtw3zwdxvoye-3lqdtkartnc24","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-xwwnmzvco4pljtw3zwdxvoye-3lqhntjzaec2g","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-xwwnmzvco4pljtw3zwdxvoye-3lqqoy5m5222f","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:30af5f","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:3e6dfe","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:531f37","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:a12119","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:b7cc01","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:d7653e","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:dd20b4","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:df5284","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:e7340d","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:e97ab5","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:f80fd4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1263195704652107778:2c31626d-8054-46b3-a6b2-f20ad7c40ca6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1263843938210852864:abd27b87-3527-4561-9c48-94a4a6c945d2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1264317116884320257:8d79a362-d964-426b-80ba-add5014648f9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1266202776109027329:acbbfb28-f3fe-4c9e-9455-555ea2ceaa5b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1266341022281408512:fe112462-60c4-4dad-9e50-a2b3c2b15588","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1266522851940671490:be331678-2f8a-4256-92ab-98f2d8314706","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1314412215202709508:3c8bfea3-d63f-4ad6-aaeb-d80776e5847a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1320464466098544640:4c7e87ad-5d60-42bd-b837-71a1fe779464","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1322631622462681090:d98412a7-889f-4bb2-870d-8c1602a32bce","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1330382399725854720:9c4dda9d-c769-4a63-bfea-9bc46f8ae136","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1332828415695740928:56a648f8-2f5c-49be-8494-6b0bf1611594","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1387130571441074176:a420cedb-106e-43e6-84f2-cdb6717197f9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1391875615784120321:c20502c6-fc6e-4d95-a204-947b2cbf76c5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1399459689109274627:aefa9973-8c02-4804-8463-eb53c1e35b33","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1413901800827232258:9232587a-3711-45e6-ade4-7d94cc21a663","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1420204067033280520:b5494a5b-aaf7-4694-9c0e-c9916c615f44","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1458133601061523464:e8bc2271-cac8-4da3-89a3-7b07403055d3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1458289443404722180:05e76c62-da9f-4951-a112-51a8f1e1b7e7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1469110901177565189:579dc3f3-61e2-443c-b184-77109aa2267d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1470543909138796545:461cff80-3ca1-4a37-926f-d2c5603f3d5f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1482376333548142593:c6f470f1-52b8-46b3-b1e0-145985f99fe3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1532846691270926344:89b0909f-ac17-4757-b7ac-ec7d8297be00","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1550257225696182272:2e2045b0-86da-4967-af68-2d1b36095981","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1589619047741550595:acc3fdc7-5c79-4fdf-8d99-6040b8692b5f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1590496892676624384:646fdd9a-075a-4697-9c09-f0f77a7c8044","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1606372870308958225:ae43f014-6fe5-452d-a190-373a709ac73b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1652862271654350848:96ca442f-a7be-451e-b7fb-4e5d6e1cde44","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1665096019212742657:adf27746-eaf1-44d0-9c0c-147eac8608d8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1690349953258786816:7e146fa3-c2cd-4f3d-ab49-c65f3b985231","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1708495816841654671:bef5da44-122d-46b4-a86a-a9bbfd77b30e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1709985163923321179:6e1033b1-168c-417f-9d92-219f5101e345","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1709985392378683498:69a8bcb7-0bbd-46a2-b05b-c308f5f157d6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1729147272624320930:269ad3e5-7c9b-4669-ad9c-d6c0eac6e943","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1729640298685317566:2dcdff53-d0b0-4f74-9946-2f67a69fada6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1730033153459302818:74cb6e63-12d4-4a63-884e-02262e4db4b0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1733921389562785821:0bf3404f-adec-4731-af8f-4b15af0278d0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1733964098902348212:4bdaffd4-8872-4850-8a60-ecda52579efa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1743657367966003451:80162536-72be-4f92-b3aa-57ad98dc8e0a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1754688383924720083:92a028a3-0781-4eea-89dd-ac66e5922646","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1754965644758409727:9f98bf62-8fcd-4e3e-a86f-9fae81c185bf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1754969138571718765:3680663f-2f61-4bd8-b7d2-cea9cd77ab92","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1755238325798015352:0747e794-d1a7-4697-bd52-579cce9b832b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1756016178403704904:14093561-bb69-4c8e-ad88-24561a69a9f6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1757416205894504729:00576e66-fa61-4c85-9f1c-101f97159167","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1794379107628880099:ea35a584-4027-4086-91be-0264771d8b80","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1796024980284543467:18d8d07c-bd68-4fbb-bca2-0f71dcc8e847","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1796909997512687675:6c837e3d-62b8-471f-bff8-60d2e5389670","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1796971625327312900:c488828a-b68c-4bed-82d1-033b24f98e99","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797017664532963474:17398ef2-f927-4e21-b1c0-da53602147c1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797101431935168538:07e7b79f-f8ae-4e3d-b1a6-4e9f0817439b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797299202386526336:144880bc-6e21-4397-8620-53c107067225","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797350863507194276:2e0774de-030c-4ca4-a331-e6e4a30e0740","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797735476759322664:dbd14331-29b9-4dcb-a8f5-ece1776c700d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797736748333830283:09c154f3-4703-4138-a947-616273c609e0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1807029311838593064:2a5be63e-9ff7-4cd5-b256-d9068e4c4ab3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1809577929413640583:67a60ceb-7ed6-42d2-a6bb-f0acd9c50433","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1848817564379713641:e07dce79-3359-4661-ac34-5ed6bc34506b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1848878093488058372:99b652f8-157d-42be-a4c1-045b8b8d6a6a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1849073292801401264:48a7d75e-f925-4fbc-8ca8-ded7ce732d36","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1849109402256904662:8080bf54-06e7-435f-99bd-e94f168f5216","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1855289706797302123:3794e871-e226-468c-b4e7-cc8793e54031","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1855652188992803156:904c89ea-40bf-4e15-9600-88ea4be16080","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1857063606275158375:23bf0a28-4eec-4111-80cd-174a0ec2f810","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1864673303862157521:e0b7ba9b-fa89-4c68-b6c5-c168db8881a1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1865829739057008793:b6eee38b-0487-4983-a196-f332a4f651ef","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1865830105341379014:0f0297b7-0cb1-4d68-956f-354916a528ee","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1865830319494160435:6ebfa31e-a1a6-4d31-acac-cc3ce12c9f5c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1865830421474504783:c117c503-8f11-491e-bef9-3eb9119f9286","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1865830428852322471:04c7e7ba-08b1-464d-8435-ec5ba58670a2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1865831572722901129:1383c702-dd38-4ea5-b730-ba7f9e68bd69","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1865831771738350026:82c168c4-1c38-4c58-a0b2-023f4ec7f1cd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1865832297544798389:45bef002-b2f2-42c6-89d1-6e2ec55fb765","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1865832480416424354:7dbd6bc9-ea8e-4fcb-a632-e1120540c661","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1865843746379804780:5875225e-ffa7-48c0-b4c1-eef7244472d9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1866186209489268874:08db25b8-8c73-44c9-8969-dab3aebc9044","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1866199755241693626:50a0f180-36e5-4767-9ffc-faed39d8c603","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1866199897562808585:86f2e63b-aa9e-46a2-85a4-e517189ffd9e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1866200786306510987:7f07d8c0-799a-4f8d-8e63-12399dada9f5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1866202336869359893:47929ff0-7027-41f2-a77e-e1c30c4c74e2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1866202503026704432:5afc0ef2-69cd-4850-9f1c-caa5d91155a1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1866253829303599533:68a3a632-72f5-443f-a58f-c05f4094e407","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1866370254751862992:42bb144b-1027-45b9-8a15-5ca3b759c6ef","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1868622984354890049:0c1991ee-57f7-4148-b392-bfc21d061893","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1872245044897624479:8c1c7566-049d-469b-9539-f10bdda28e11","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1872688225187447127:a672cf5c-dc22-40ce-a8af-a0e2b6a035ed","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1900415378494296551:421d89d1-fe57-4fe4-868e-589a23ce4183","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1937592902105862583:bd1780f0-dc64-438c-b460-49e49377132c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1945271140668379620:4348b643-91f1-4f15-b839-1bcc7bad7043","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1945379269846483371:36cfc365-eb01-44e2-99d6-d4701c482726","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1945792165461799000:f2425c4e-a9f2-47af-893d-816279774143","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1945845230751654224:8112d7b3-e199-4456-9a46-77423a1f46b8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1946918018162081864:1867d421-300f-41a2-a702-c791b59b0e92","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1978516176566141373:777ea400-a957-4449-bf53-b9c430e68481","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1981474786556432731:6eb1c351-4870-4175-969b-c86e9750e69f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1981488154650825113:9a062a74-5e01-4d54-bc78-9e209c9d11a5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1981553244351713761:6895e802-4f89-4b05-be6e-7eab5e546a48","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1981707379931570273:9bcdf9da-1c56-4939-badb-bb408cb1c306","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1981758514134405142:3c53f0fc-5df1-4cc0-9e0b-c374bf504527","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1986433391160418717:1c462731-c61d-4a78-84fd-c208d957b0b5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1989017415607275908:507c974e-457e-42b6-aee7-177dd33bb9e1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1993073630004019472:31815733-1901-4d49-8dc2-f04a90d86ebf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1996973673572425892:c7850cfd-75d8-419a-be59-ca8f8223bbba","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1997679346467905948:390a9c74-5504-4c01-9711-dfa16ef51d10","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1997777381101035925:f89ca971-5624-4fde-8bba-8e191b1ac99d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1998440120433746086:765449d8-7b02-48a9-b703-106ee0ed0a0d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2041259723161559387:dc278587-4925-476c-9989-94093f026495","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2045358042217410917:e8457d24-0542-4c68-8b28-7a8a9ab5cb3b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060490594112115178:1cc33e02-1e7d-46b1-885b-372548738e85","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060501509109108924:5f7a5774-317b-4ea3-97e5-f968422451f2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061160639632982093:982f589e-4049-439c-85b0-bf96cc26a3df","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2066489681747837054:dbdd3cae-0486-4bfe-81e3-da448b937548","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2085422866741502072:7fc953e6-d522-4c06-a164-067e0982aed1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2093030154792735198:59963741-83c3-439f-9378-271f1f8bce9d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095914533629923802:a8a5f43a-e21f-43c0-adba-dffef8826162","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2098154600188551658:6fd4ec93-3d85-494d-a263-58a9ef4511d4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102899187511877652:fc1268f9-9b06-49a6-96c1-fb7c9bdf2386","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2104981009192153232:aee2a638-e67f-4d01-9596-f2093a411567","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2105001864500789688:8497a754-59c4-4011-af62-b22b6f10fd26","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107139635952451804:66c218e3-b6e6-4ced-871c-9eecc7228890","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2108164153471119496:5e51b69f-3993-4181-bae5-765bef2cc997","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2109388762799112689:02b22d71-1668-4f32-a307-225be42b890e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2111454069005148455:6978697d-f43a-40da-ace6-078f048d6cb8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112166882803617914:c117d14a-a3cd-4ead-a91e-2dc7d83352bb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_video:1949809177586548794","quote_policy":"short_quote_link_out"},{"id":"mcp:x_video:2103010871827980772","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:-M6nziUJMQA","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:8BltPH0agX4","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:B0FbREFwTWM","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:CAcVZ2cmZPc","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:CLhBI3UXWyg","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:DURzUWnnkTY","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:GBpTaDf_E34","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:IUkkT-zPRks","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:KjVlxhTMrVw","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:LtQUBCWKJVE","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:S3nCflWpmCI","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:T01RUYyDFoo","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:WmfRAAI2ock","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:YBmC03FtNoE","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:ZFU30OX2Xn8","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:cR11fde3oN4","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:cm_fO3am7YM","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:dSri15qE2P0","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:eqStruDaRX0","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:nieMh9Jh5Ow","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:nsDYbKuRAtI","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:q5tNz_Ks9zk","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:r1ePbPcftUE","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:t4zxnoPxxrg","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":6,"other":0,"podcast":11,"publication":0,"registry":0,"regulatory":0,"x_thread":123,"x_video":2,"youtube":24},"by_evidence_role":{"commentary":166},"count":166,"evidence_window":{"end":"2026-10-19","start":"2020-05-20"},"retrieval_snapshot":"2026-10-24T14:15:48.700111Z","timeline":[{"count":3,"week":"2020-W21"},{"count":3,"week":"2020-W22"},{"count":1,"week":"2020-W25"},{"count":1,"week":"2020-W41"},{"count":1,"week":"2020-W43"},{"count":2,"week":"2020-W44"},{"count":1,"week":"2020-W47"},{"count":1,"week":"2020-W48"},{"count":1,"week":"2021-W13"},{"count":1,"week":"2021-W17"},{"count":1,"week":"2021-W19"},{"count":1,"week":"2021-W22"},{"count":1,"week":"2021-W27"},{"count":1,"week":"2021-W30"},{"count":2,"week":"2021-W45"},{"count":1,"week":"2021-W49"},{"count":1,"week":"2021-W50"},{"count":1,"week":"2022-W02"},{"count":1,"week":"2022-W03"},{"count":1,"week":"2022-W22"},{"count":1,"week":"2022-W29"},{"count":2,"week":"2022-W45"},{"count":1,"week":"2022-W46"},{"count":1,"week":"2022-W51"},{"count":1,"week":"2022-W52"},{"count":1,"week":"2023-W18"},{"count":1,"week":"2023-W22"},{"count":1,"week":"2023-W32"},{"count":1,"week":"2023-W39"},{"count":3,"week":"2023-W40"},{"count":3,"week":"2023-W48"},{"count":2,"week":"2023-W49"},{"count":1,"week":"2023-W50"},{"count":1,"week":"2024-W01"},{"count":1,"week":"2024-W02"},{"count":5,"week":"2024-W06"},{"count":1,"week":"2024-W07"},{"count":1,"week":"2024-W11"},{"count":1,"week":"2024-W19"},{"count":1,"week":"2024-W21"},{"count":7,"week":"2024-W22"},{"count":3,"week":"2024-W23"},{"count":1,"week":"2024-W24"},{"count":1,"week":"2024-W25"},{"count":2,"week":"2024-W26"},{"count":1,"week":"2024-W27"},{"count":1,"week":"2024-W40"},{"count":1,"week":"2024-W41"},{"count":2,"week":"2024-W42"},{"count":5,"week":"2024-W43"},{"count":1,"week":"2024-W44"},{"count":3,"week":"2024-W45"},{"count":1,"week":"2024-W46"},{"count":1,"week":"2024-W48"},{"count":12,"week":"2024-W49"},{"count":8,"week":"2024-W50"},{"count":1,"week":"2024-W51"},{"count":2,"week":"2024-W52"},{"count":1,"week":"2025-W03"},{"count":1,"week":"2025-W08"},{"count":1,"week":"2025-W11"},{"count":1,"week":"2025-W18"},{"count":3,"week":"2025-W22"},{"count":2,"week":"2025-W23"},{"count":2,"week":"2025-W26"},{"count":6,"week":"2025-W29"},{"count":1,"week":"2025-W30"},{"count":2,"week":"2025-W31"},{"count":2,"week":"2025-W42"},{"count":5,"week":"2025-W43"},{"count":1,"week":"2025-W45"},{"count":1,"week":"2025-W46"},{"count":1,"week":"2025-W48"},{"count":3,"week":"2025-W49"},{"count":1,"week":"2025-W50"},{"count":2,"week":"2025-W51"},{"count":2,"week":"2026-W01"},{"count":1,"week":"2026-W15"},{"count":1,"week":"2026-W16"},{"count":3,"week":"2026-W22"},{"count":1,"week":"2026-W23"},{"count":1,"week":"2026-W25"},{"count":1,"week":"2026-W27"},{"count":1,"week":"2026-W30"},{"count":1,"week":"2026-W32"},{"count":1,"week":"2026-W35"},{"count":1,"week":"2026-W36"},{"count":2,"week":"2026-W37"},{"count":1,"week":"2026-W38"},{"count":4,"week":"2026-W39"},{"count":4,"week":"2026-W40"},{"count":4,"week":"2026-W41"},{"count":1,"week":"2026-W42"},{"count":1,"week":"2026-W43"}],"undated_sources":1}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: belantamab mafodotin","status":"unmapped"},{"brand_names":["Revlimid"],"label":"lenalidomide","slug":"lenalidomide"},{"brand_names":["Decadron","Dexacen-4","Dexone","Hemady","Hexadrol","Taperdex"],"label":"dexamethasone","slug":"dexamethasone"},{"brand_names":["Darzalex"],"label":"daratumumab","slug":"daratumumab"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Multiple myeloma","slug":"multiple-myeloma"},{"reason":"Unmapped registry condition: Newly Diagnosed Multiple Myeloma","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"DREAMM-10","aliases":["DREAMM-10","A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)","A Phase 3, Randomized, Open-label Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)"],"brief_title":"A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Multiple Myeloma","Newly Diagnosed Multiple Myeloma"],"enrollment":{"count":520,"type":"ESTIMATED"},"interventions":[{"name":"Belantamab mafodotin","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Lenalidomide","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Dexamethasone","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Daratumumab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT06679101","official_title":"A Phase 3, Randomized, Open-label Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)","overall_status":"RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2031-04-28","type":"ESTIMATED"},"primary_endpoints":[{"description":"Defined as the time from the date of randomization to the date of first documented PD per International Myeloma Working Group (IMWG) criteria by Independent Review Committee (IRC) or death from any cause in the absence of progression, whichever occurs first.","measure":"PFS","timeFrame":"Up to approximately 7 years"},{"description":"Defined as achieving MRD negativity at 10\\^-5 sensitivity threshold (1 nucleated tumor cell in 100,000 normal cells) assessed by next-generation sequencing (NGS) at least once during the time of confirmed complete response (CR) or better response per IMWG criteria by IRC.","measure":"Number of Participants Achieving MRD Negative Status","timeFrame":"Up to approximately 7 years"}],"registry_last_updated":"2026-04-22","registry_url":"https://clinicaltrials.gov/study/NCT06679101","short_name":"DREAMM-10","short_name_basis":"registry_acronym","sponsor":"GlaxoSmithKline","start_date":{"date":"2024-12-16","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"214828","type":"sponsor_study_id"},{"domain":"CTIS","id":"2024-516030-35","type":"registry"}],"study_type":"INTERVENTIONAL"}}}